Skip to Content

New Drug Approvals Archive - May 2019

See also: New Indications and Dosage Forms for May 2019

May 2019

Dengvaxia (dengue tetravalent vaccine, live) Injection

Date of Approval: May 1, 2019
Company: Sanofi Pasteur, Inc.
Treatment for: Prevention of Dengue Disease

Dengvaxia (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue caused by dengue virus serotypes 1, 2, 3 and 4 in people 9 years through 16 years of age living in endemic areas who have laboratory-confirmed previous dengue infection.

Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) Extended-Release Tablets

Date of Approval: May 2, 2019
Company: AstraZeneca
Treatment for: Diabetes Type 2

Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Vyndaqel (tafamidis meglumine) Capsules

Date of Approval: May 3, 2019
Company: Pfizer Inc.
Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis

Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.

Ruzurgi (amifampridine) Tablets

Date of Approval: May 6, 2019
Company: Jacobus Pharmaceutical Company, Inc.
Treatment for: Lambert-Eaton Myasthenic Syndrome

Ruzurgi (amifampridine) is a potassium-channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age.

Nayzilam (midazolam) Nasal Spray

Date of Approval: May 17, 2019
Company: UCB
Treatment for: Seizure Clusters

Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters.

Piqray (alpelisib) Tablets

Date of Approval: May 24, 2019
Company: Novartis
Treatment for: Breast Cancer

Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2-negative, PIK3CA-mutated breast cancer.

Zolgensma (onasemnogene abeparvovec-xioi) Suspension for Intravenous Infusion

Date of Approval: May 24, 2019
Company: Novartis
Treatment for: Spinal Muscular Atrophy

Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA).

Slynd (drospirenone) Tablets

Date of Approval: May 23, 2019
Company: Exeltis
Treatment for: Contraception

Slynd (drospirenone) is a progestin oral contraceptive for birth control.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.